Abstract A05: Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance's Gen 2 process from advanced bladder cancer for adoptive immunotherapy
Qiang Li(Nanchang University), Gurkamal Chatta(Roswell Park Comprehensive Cancer Center), Cécile Chartier(Io Therapeutics (United States)), Kunle Odunsi(University of Chicago), Kenneth Onimus(Covance (United States)), Amit A. Lugade(Roswell Park Comprehensive Cancer Center), Maria Fardis(Pharmacyclics (United States)), Elizabeth Brese, Arvind Natarajan(Sri Devaraj Urs Medical College), Anand Veerapathran(Covance (United States)), Khurshid A. Guru(Roswell Park Comprehensive Cancer Center), Adrian Wells(Covance (United States))
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor
|The Journal of Immunology|2005|938